EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: Stock

Company

Edwards

2024/04/17 22:00:02

Price **87.24**

USD

Tel: +1-949-250-2500

Difference -3.12%(-2.81)



05.2023 07.2023 09.2023 11.2023 01.2024 03.2024

Contact Details

EDWARDS

LIFESCIENCES CORP.

Fax: +

1 Edwards Way

Web: http://www.edwards.com

92614 Irvine E-mail:

customerservice_us@edwards.com

Company Profile

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

60.00

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 2023 | | 2022 | | 2021 | |
|--------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets I | Liabilities and equity |
| Current assets | 4,035,700,000 | | 3,095,800,000 | | 3,180,700,000 | |
| Common stock capital | | 650,500,000 | | 646,300,000 | | 642,000,000 |
| Fixed assets | 5,327,500,000 | | 5,196,700,000 | | 5,321,900,000 | |
| Equity capital of a company | | 6,719,400,000 | | 5,806,700,000 | | 5,835,900,000 |
| Cash and cash equivalents | 1,147,300,000 | | 769,500,000 | | 864,300,000 | |
| Accrued liabilities | | 433,500,000 | | 410,500,000 | | 450,300,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 1,195,400,000 | | 1,022,400,000 | | 1,032,300,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 1,448,400,000 | | 1,463,400,000 | | 1,634,400,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 344,900,000 | | 387,100,000 | | 519,300,000 |
| Total assets | 9,363,200,000 | 9,363,200,000 | 8,292,500,000 | 8,292,500,000 | 8,502,600,000 | 8,502,600,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 19,800 | 17,300 | 15,700 |
| Equity ratio | 72.51% | 70.02% | 68.64% |
| Debt-equity ratio | 37.92% | 42.81% | 45.69% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | 12.43% | 13.89% | 11.69% |

EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: Stock

| Income statement | | | |
|--|---------------|---------------|---------------|
| | 2023 | 2022 | 2021 |
| Turnover | 6,004,800,000 | 5,382,400,000 | 5,232,500,000 |
| Net income | 1,402,400,000 | 1,521,900,000 | 1,503,100,000 |
| EBIT | 1,463,942,480 | 1,654,723,720 | 1,608,887,280 |
| Operating income before taxes | 1,598,100,000 | 1,767,400,000 | 1,702,000,000 |
| Cash Flow | 895,800,000 | 1,218,200,000 | 1,732,100,000 |
| Net interest income | 42,700,000 | 9,300,000 | -7,400,000 |
| Research and development expenses | 1,071,800,000 | 945,200,000 | 903,100,000 |
| Income taxes | 198,700,000 | 245,500,000 | 198,900,000 |
| Result from investments in subsidaries, associates and other | - | - | - |
| Revenues per employee | 285,440 | 292,827 | 313,683 |

Board of Directors

| Members of Management Board | | |
|-----------------------------|--------------------------------|--|
| | | |
| Michael Mussallem | Chairman of Board of Directors | |
| Nicholas Valeriani | Member of Board of Directors | |
| Kieran Gallahue | Member of Board of Directors | |
| Leslie Heisz | Member of Board of Directors | |
| Martha Marsh | Member of Board of Directors | |
| Paul LaViolette | Member of Board of Directors | |
| Ramona Sequeira | Member of Board of Directors | |
| Steven Loranger | Member of Board of Directors | |
| Arnold A. Pinkston | Member of Executive Committee | |
| Bernard J. Zovighian | Member of Executive Committee | |
| Catherine M. Szyman | Member of Executive Committee | |
| Christine Z. McCauley | Member of Executive Committee | |
| Daveen Chopra | Member of Executive Committee | |
| Dirksen J. Lehman | Member of Executive Committee | |
| Donald E. Bobo, Jr. | Member of Executive Committee | |
| Gary I. Sorsher | Member of Executive Committee | |
| Jean-Luc Lemercier | Member of Executive Committee | |
| Joseph Nuzzolese | Member of Executive Committee | |
| Larry L. Wood | Member of Executive Committee | |
| Scott B. Ullem | Member of Executive Committee | |
| Todd J. Brinton | Member of Executive Committee | |
| Wayne Markowitz | Member of Executive Committee | |